# 68 Ga-PSMA for High Risk Prostate Cancer

> **NCT04614363** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 80 (actual)

## Conditions studied

- Prostate Cancer
- High Risk

## Interventions

- **DRUG:** 68Ga-PSMA

## Key facts

- **NCT ID:** NCT04614363
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-13
- **Primary completion:** 2022-02-26
- **Final completion:** 2023-04-25
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614363, "68 Ga-PSMA for High Risk Prostate Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT04614363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*